Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 5914e470-3f8e-4d98-addc-fdb60423a188

KENALOG-40

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2026-01-05
Captured
2026-09-09T23:37:47.659725+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
Full extracted label fields
application numbers
  1. NDA014901
boxed warning exact
    brand names
    1. KENALOG-40
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
    generic names
    1. TRIAMCINOLONE ACETONIDE
    id
    5914e470-3f8e-4d98-addc-fdb60423a188
    indications and usage exact
    1. INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
    indications and usage tables exact
      is original packager
        manufacturer names
        1. A-S Medication Solutions
        matched search terms
        1. cancer
        2. lymphomas
        3. tumor
        package ndcs
        1. 50090-0819-0
        product ndcs
        1. 50090-0819
        product types
        1. HUMAN PRESCRIPTION DRUG
        recent major changes exact
          record type
          complete_spl_indications_section_candidate
          routes
          1. INTRA-ARTICULAR
          2. INTRAMUSCULAR
          rxcuis
          1. 1085754
          2. 1085756
          source batch
          file
          /private/tmp/cancer-full-research/indications/raw/labels-00300.json
          meta
          disclaimer
          Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
          last updated
          2026-09-09
          results
          limit
          100
          skip
          300
          total
          830
          sha256
          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
          url
          https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=300&sort=id%3Aasc
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
          spl effective date
          2026-01-05
          spl effective time
          20260105
          spl set id
          4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
          spl version
          23
          substance names
          1. TRIAMCINOLONE ACETONIDE
          uniis
          1. F446C597KA
          verification flags
          1. oncology_keyword_candidate_not_clinically_classified
          2. spl_text_not_verified_identical_to_latest_approved_label
          3. individual_indications_not_split_or_reconciled
          4. not_identified_as_original_packager
          Drugs@FDA application source records
          1. application number
            NDA014901
            payload
            all indexed label documents
            1. Appl No
              014901
              Application Docs Date
              2006-11-22 00:00:00
              Application Docs ID
              10850
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              34
              Submission Type
              SUPPL
            2. Appl No
              014901
              Application Docs Date
              2010-02-04 00:00:00
              Application Docs ID
              10851
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              37
              Submission Type
              SUPPL
            3. Appl No
              014901
              Application Docs Date
              2014-07-09 00:00:00
              Application Docs ID
              10852
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              42
              Submission Type
              SUPPL
            4. Appl No
              014901
              Application Docs Date
              2011-06-16 00:00:00
              Application Docs ID
              33127
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              38
              Submission Type
              SUPPL
            5. Appl No
              014901
              Application Docs Date
              2011-07-18 00:00:00
              Application Docs ID
              33128
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              39
              Submission Type
              SUPPL
            6. Appl No
              014901
              Application Docs Date
              2018-04-01 00:00:00
              Application Docs ID
              53573
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              44
              Submission Type
              SUPPL
            7. Appl No
              014901
              Application Docs Date
              2018-06-28 00:00:00
              Application Docs ID
              54712
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              45
              Submission Type
              SUPPL
            8. Appl No
              014901
              Application Docs Date
              2020-05-19 00:00:00
              Application Docs ID
              63087
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              47
              Submission Type
              SUPPL
            9. Appl No
              014901
              Application Docs Date
              2024-06-06 00:00:00
              Application Docs ID
              78680
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              54
              Submission Type
              SUPPL
            10. Appl No
              014901
              Application Docs Date
              2024-11-18 00:00:00
              Application Docs ID
              80226
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              55
              Submission Type
              SUPPL
            all submission records
            1. Appl No
              014901
              Review Priority
              N/A
              Submission Class Code ID
              4
              Submission No
              55
              Submission Status
              AP
              Submission Status Date
              2024-08-09 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            2. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              54
              Submission Status
              AP
              Submission Status Date
              2024-06-05 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            3. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              4
              Submission No
              47
              Submission Status
              AP
              Submission Status Date
              2019-04-12 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            4. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              45
              Submission Status
              AP
              Submission Status Date
              2018-06-22 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            5. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              44
              Submission Status
              AP
              Submission Status Date
              2018-03-29 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            6. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              4
              Submission No
              43
              Submission Status
              AP
              Submission Status Date
              2015-10-26 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            7. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              42
              Submission Status
              AP
              Submission Status Date
              2014-07-03 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            8. Appl No
              014901
              Review Priority
              UNKNOWN
              Submission Class Code ID
              3
              Submission No
              39
              Submission Status
              AP
              Submission Status Date
              2011-07-15 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            9. Appl No
              014901
              Review Priority
              UNKNOWN
              Submission Class Code ID
              3
              Submission No
              38
              Submission Status
              AP
              Submission Status Date
              2011-06-16 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            10. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              37
              Submission Status
              AP
              Submission Status Date
              2010-01-28 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            11. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              4
              Submission No
              35
              Submission Status
              AP
              Submission Status Date
              2001-01-05 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            12. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              34
              Submission Status
              AP
              Submission Status Date
              2006-11-20 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            application number
            NDA014901
            approval interpretation
            Application linkage and approved submission are not indication-level current approval verification
            current indication status
            not_reconciled
            has approved submission record
            true
            latest approved submission date
            2024-08-09
            latest label selection rule
            max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
            latest posted label documents
            1. Appl No
              014901
              Application Docs Date
              2024-11-18 00:00:00
              Application Docs ID
              80226
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              55
              Submission Type
              SUPPL
            official application record
            Appl No
            014901
            Appl Public Notes
            Appl Type
            NDA
            Sponsor Name
            APOTHECON
            openfda application present
            true
            products
            1. Active Ingredient
              TRIAMCINOLONE ACETONIDE
              Appl No
              014901
              Drug Name
              KENALOG-40
              Form
              INJECTABLE;INJECTION
              Product No
              001
              Reference Drug
              1
              Reference Standard
              1
              Strength
              40MG/ML
              marketing status
              1. Prescription
            2. Active Ingredient
              TRIAMCINOLONE ACETONIDE
              Appl No
              014901
              Drug Name
              KENALOG-80
              Form
              INJECTABLE;INJECTION
              Product No
              002
              Reference Drug
              1
              Reference Standard
              1
              Strength
              80MG/ML
              marketing status
              1. Prescription

          Source passages and status connections

          Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

          Passage 1 · indication intro context
          application numbers
          1. NDA014901
          brand names
          1. KENALOG-40
          classification reasons
          1. explicit_positive_indication_predicate
          2. no_tumor_directed_keyword_in_positive_statement
          3. incomplete_colon_led_indication_intro
          clinical review status
          pending
          content role
          indication_intro_context
          context span
          end
          755
          end exclusive
          true
          exact text
          INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or
          label id
          5914e470-3f8e-4d98-addc-fdb60423a188
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
          start
          0
          current approval status
          not_reconciled
          duplicate text group
          dup-f51c7b0b42b374f8fd91
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. TRIAMCINOLONE ACETONIDE
          id
          ind-span-39cad62fbddcdba4427c
          label id
          5914e470-3f8e-4d98-addc-fdb60423a188
          positive predicate support span
          end
          228
          end exclusive
          true
          exact text
          is indicated
          label id
          5914e470-3f8e-4d98-addc-fdb60423a188
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
          start
          216
          qualifier mentions
            regulatory links
              schema version
              0.1.0
              source batch sha256
              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
              source defined aliases
                source span
                end
                555
                end exclusive
                true
                exact text
                INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
                label id
                5914e470-3f8e-4d98-addc-fdb60423a188
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                start
                0
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                spl effective date
                2026-01-05
                spl set id
                4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                spl version
                23
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                not_applicable
                Passage 2 · unclassified context
                application numbers
                1. NDA014901
                brand names
                1. KENALOG-40
                classification reasons
                1. no_unambiguous_positive_indication_predicate
                clinical review status
                pending
                content role
                unclassified_context
                context span
                end
                923
                end exclusive
                true
                exact text
                ate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where a
                label id
                5914e470-3f8e-4d98-addc-fdb60423a188
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                start
                356
                current approval status
                not_reconciled
                duplicate text group
                dup-c653eb79e6eebe27ac29
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. TRIAMCINOLONE ACETONIDE
                id
                ind-span-947dd8da0248a42c2cd7
                label id
                5914e470-3f8e-4d98-addc-fdb60423a188
                positive predicate support span
                Source null
                qualifier mentions
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                    source defined aliases
                      source span
                      end
                      723
                      end exclusive
                      true
                      exact text
                      Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
                      label id
                      5914e470-3f8e-4d98-addc-fdb60423a188
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                      start
                      556
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                      spl effective date
                      2026-01-05
                      spl set id
                      4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                      spl version
                      23
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      unclear
                      Passage 3 · unclassified context
                      application numbers
                      1. NDA014901
                      brand names
                      1. KENALOG-40
                      classification reasons
                      1. no_unambiguous_positive_indication_predicate
                      clinical review status
                      pending
                      content role
                      unclassified_context
                      context span
                      end
                      1307
                      end exclusive
                      true
                      exact text
                      ickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamo
                      label id
                      5914e470-3f8e-4d98-addc-fdb60423a188
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                      start
                      524
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-89a3c0dc58a1d9ced9ff
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. TRIAMCINOLONE ACETONIDE
                      id
                      ind-span-62ed1eab9b59ccedee03
                      label id
                      5914e470-3f8e-4d98-addc-fdb60423a188
                      positive predicate support span
                      Source null
                      qualifier mentions
                        regulatory links
                          schema version
                          0.1.0
                          source batch sha256
                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                          source defined aliases
                            source span
                            end
                            1107
                            end exclusive
                            true
                            exact text
                            Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
                            label id
                            5914e470-3f8e-4d98-addc-fdb60423a188
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                            start
                            724
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                            spl effective date
                            2026-01-05
                            spl set id
                            4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                            spl version
                            23
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            unclear
                            Passage 4 · unclassified context
                            application numbers
                            1. NDA014901
                            brand names
                            1. KENALOG-40
                            classification reasons
                            1. no_unambiguous_positive_indication_predicate
                            clinical review status
                            pending
                            content role
                            unclassified_context
                            context span
                            end
                            1438
                            end exclusive
                            true
                            exact text
                            ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic
                            label id
                            5914e470-3f8e-4d98-addc-fdb60423a188
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                            start
                            908
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-1d02c19663bc425697c2
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. TRIAMCINOLONE ACETONIDE
                            id
                            ind-span-2befaacf78032b74899c
                            label id
                            5914e470-3f8e-4d98-addc-fdb60423a188
                            positive predicate support span
                            Source null
                            qualifier mentions
                              regulatory links
                                schema version
                                0.1.0
                                source batch sha256
                                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                source defined aliases
                                  source span
                                  end
                                  1238
                                  end exclusive
                                  true
                                  exact text
                                  Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
                                  label id
                                  5914e470-3f8e-4d98-addc-fdb60423a188
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                  start
                                  1108
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                  spl effective date
                                  2026-01-05
                                  spl set id
                                  4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                  spl version
                                  23
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  unclear
                                  Passage 5 · unclassified context
                                  application numbers
                                  1. NDA014901
                                  brand names
                                  1. KENALOG-40
                                  classification reasons
                                  1. no_unambiguous_positive_indication_predicate
                                  clinical review status
                                  pending
                                  content role
                                  unclassified_context
                                  context span
                                  end
                                  1595
                                  end exclusive
                                  true
                                  exact text
                                  a, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neopla
                                  label id
                                  5914e470-3f8e-4d98-addc-fdb60423a188
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                  start
                                  1039
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-f29f21b615e270d6115c
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. TRIAMCINOLONE ACETONIDE
                                  id
                                  ind-span-bd8bd08c0a449a62a491
                                  label id
                                  5914e470-3f8e-4d98-addc-fdb60423a188
                                  positive predicate support span
                                  Source null
                                  qualifier mentions
                                    regulatory links
                                      schema version
                                      0.1.0
                                      source batch sha256
                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                      source defined aliases
                                        source span
                                        end
                                        1395
                                        end exclusive
                                        true
                                        exact text
                                        Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
                                        label id
                                        5914e470-3f8e-4d98-addc-fdb60423a188
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                        start
                                        1239
                                        source url
                                        https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                        spl effective date
                                        2026-01-05
                                        spl set id
                                        4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                        spl version
                                        23
                                        structured fields status
                                        not_extracted_no_values_inferred_from_mentions
                                        structured indication
                                        age
                                        Source null
                                        approval pathway
                                        Source null
                                        biomarker and test
                                        Source null
                                        disease stage
                                        Source null
                                        limitations
                                        Source null
                                        line
                                        Source null
                                        prior therapy
                                        Source null
                                        regimen
                                        Source null
                                        tumor histology
                                        Source null
                                        use intent
                                        unclear
                                        Passage 6 · unclassified context
                                        application numbers
                                        1. NDA014901
                                        brand names
                                        1. KENALOG-40
                                        classification reasons
                                        1. no_unambiguous_positive_indication_predicate
                                        clinical review status
                                        pending
                                        content role
                                        unclassified_context
                                        context span
                                        end
                                        1788
                                        end exclusive
                                        true
                                        exact text
                                        regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tu
                                        label id
                                        5914e470-3f8e-4d98-addc-fdb60423a188
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                        start
                                        1196
                                        current approval status
                                        not_reconciled
                                        duplicate text group
                                        dup-a906829f3acc61d551b2
                                        extraction review status
                                        automated_candidate_pending_source_review
                                        generic names
                                        1. TRIAMCINOLONE ACETONIDE
                                        id
                                        ind-span-d4d129b6accd895c95cc
                                        label id
                                        5914e470-3f8e-4d98-addc-fdb60423a188
                                        positive predicate support span
                                        Source null
                                        qualifier mentions
                                          regulatory links
                                            schema version
                                            0.1.0
                                            source batch sha256
                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                            source defined aliases
                                              source span
                                              end
                                              1588
                                              end exclusive
                                              true
                                              exact text
                                              Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
                                              label id
                                              5914e470-3f8e-4d98-addc-fdb60423a188
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                              start
                                              1396
                                              source url
                                              https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                              spl effective date
                                              2026-01-05
                                              spl set id
                                              4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                              spl version
                                              23
                                              structured fields status
                                              not_extracted_no_values_inferred_from_mentions
                                              structured indication
                                              age
                                              Source null
                                              approval pathway
                                              Source null
                                              biomarker and test
                                              Source null
                                              disease stage
                                              Source null
                                              limitations
                                              Source null
                                              line
                                              Source null
                                              prior therapy
                                              Source null
                                              regimen
                                              Source null
                                              tumor histology
                                              Source null
                                              use intent
                                              unclear
                                              Passage 7 · unclassified context
                                              application numbers
                                              1. NDA014901
                                              brand names
                                              1. KENALOG-40
                                              classification reasons
                                              1. no_unambiguous_positive_indication_predicate
                                              clinical review status
                                              pending
                                              content role
                                              unclassified_context
                                              context span
                                              end
                                              1867
                                              end exclusive
                                              true
                                              exact text
                                              penia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteri
                                              label id
                                              5914e470-3f8e-4d98-addc-fdb60423a188
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                              start
                                              1389
                                              current approval status
                                              not_reconciled
                                              duplicate text group
                                              dup-5bacbe7f7c9ff19a5482
                                              extraction review status
                                              automated_candidate_pending_source_review
                                              generic names
                                              1. TRIAMCINOLONE ACETONIDE
                                              id
                                              ind-span-f6433b79643c8d1041be
                                              label id
                                              5914e470-3f8e-4d98-addc-fdb60423a188
                                              positive predicate support span
                                              Source null
                                              qualifier mentions
                                                regulatory links
                                                  schema version
                                                  0.1.0
                                                  source batch sha256
                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                  source defined aliases
                                                    source span
                                                    end
                                                    1667
                                                    end exclusive
                                                    true
                                                    exact text
                                                    Neoplastic diseases: For the palliative management of leukemias and lymphomas.
                                                    label id
                                                    5914e470-3f8e-4d98-addc-fdb60423a188
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                    start
                                                    1589
                                                    source url
                                                    https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                    spl effective date
                                                    2026-01-05
                                                    spl set id
                                                    4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                    spl version
                                                    23
                                                    structured fields status
                                                    not_extracted_no_values_inferred_from_mentions
                                                    structured indication
                                                    age
                                                    Source null
                                                    approval pathway
                                                    Source null
                                                    biomarker and test
                                                    Source null
                                                    disease stage
                                                    Source null
                                                    limitations
                                                    Source null
                                                    line
                                                    Source null
                                                    prior therapy
                                                    Source null
                                                    regimen
                                                    Source null
                                                    tumor histology
                                                    Source null
                                                    use intent
                                                    unclear
                                                    Passage 8 · unclassified context
                                                    application numbers
                                                    1. NDA014901
                                                    brand names
                                                    1. KENALOG-40
                                                    classification reasons
                                                    1. no_unambiguous_positive_indication_predicate
                                                    clinical review status
                                                    pending
                                                    content role
                                                    unclassified_context
                                                    context span
                                                    end
                                                    2006
                                                    end exclusive
                                                    true
                                                    exact text
                                                    berculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission o
                                                    label id
                                                    5914e470-3f8e-4d98-addc-fdb60423a188
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                    start
                                                    1468
                                                    current approval status
                                                    not_reconciled
                                                    duplicate text group
                                                    dup-4d0bd2ed812590697a9a
                                                    extraction review status
                                                    automated_candidate_pending_source_review
                                                    generic names
                                                    1. TRIAMCINOLONE ACETONIDE
                                                    id
                                                    ind-span-c243299b53156b1ca9fb
                                                    label id
                                                    5914e470-3f8e-4d98-addc-fdb60423a188
                                                    positive predicate support span
                                                    Source null
                                                    qualifier mentions
                                                    1. context exact
                                                      ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
                                                      kind
                                                      biomarker
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1805
                                                      end exclusive
                                                      true
                                                      exact text
                                                      metastatic brain tumor or craniotomy
                                                      label id
                                                      5914e470-3f8e-4d98-addc-fdb60423a188
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                      start
                                                      1769
                                                    2. context exact
                                                      ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
                                                      kind
                                                      stage_or_setting
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1805
                                                      end exclusive
                                                      true
                                                      exact text
                                                      metastatic brain tumor or craniotomy
                                                      label id
                                                      5914e470-3f8e-4d98-addc-fdb60423a188
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                      start
                                                      1769
                                                    regulatory links
                                                      schema version
                                                      0.1.0
                                                      source batch sha256
                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                      source defined aliases
                                                        source span
                                                        end
                                                        1806
                                                        end exclusive
                                                        true
                                                        exact text
                                                        Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
                                                        label id
                                                        5914e470-3f8e-4d98-addc-fdb60423a188
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                        start
                                                        1668
                                                        source url
                                                        https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                        spl effective date
                                                        2026-01-05
                                                        spl set id
                                                        4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                        spl version
                                                        23
                                                        structured fields status
                                                        not_extracted_no_values_inferred_from_mentions
                                                        structured indication
                                                        age
                                                        Source null
                                                        approval pathway
                                                        Source null
                                                        biomarker and test
                                                        Source null
                                                        disease stage
                                                        Source null
                                                        limitations
                                                        Source null
                                                        line
                                                        Source null
                                                        prior therapy
                                                        Source null
                                                        regimen
                                                        Source null
                                                        tumor histology
                                                        Source null
                                                        use intent
                                                        unclear
                                                        Passage 9 · unclassified context
                                                        application numbers
                                                        1. NDA014901
                                                        brand names
                                                        1. KENALOG-40
                                                        classification reasons
                                                        1. no_unambiguous_positive_indication_predicate
                                                        clinical review status
                                                        pending
                                                        content role
                                                        unclassified_context
                                                        context span
                                                        end
                                                        2156
                                                        end exclusive
                                                        true
                                                        exact text
                                                        s: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulm
                                                        label id
                                                        5914e470-3f8e-4d98-addc-fdb60423a188
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                        start
                                                        1607
                                                        current approval status
                                                        not_reconciled
                                                        duplicate text group
                                                        dup-7ffcadd4ee0ac9c57690
                                                        extraction review status
                                                        automated_candidate_pending_source_review
                                                        generic names
                                                        1. TRIAMCINOLONE ACETONIDE
                                                        id
                                                        ind-span-f859a1f77d154f38b1ed
                                                        label id
                                                        5914e470-3f8e-4d98-addc-fdb60423a188
                                                        positive predicate support span
                                                        Source null
                                                        qualifier mentions
                                                          regulatory links
                                                            schema version
                                                            0.1.0
                                                            source batch sha256
                                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                            source defined aliases
                                                              source span
                                                              end
                                                              1956
                                                              end exclusive
                                                              true
                                                              exact text
                                                              Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
                                                              label id
                                                              5914e470-3f8e-4d98-addc-fdb60423a188
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                              start
                                                              1807
                                                              source url
                                                              https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                              spl effective date
                                                              2026-01-05
                                                              spl set id
                                                              4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                              spl version
                                                              23
                                                              structured fields status
                                                              not_extracted_no_values_inferred_from_mentions
                                                              structured indication
                                                              age
                                                              Source null
                                                              approval pathway
                                                              Source null
                                                              biomarker and test
                                                              Source null
                                                              disease stage
                                                              Source null
                                                              limitations
                                                              Source null
                                                              line
                                                              Source null
                                                              prior therapy
                                                              Source null
                                                              regimen
                                                              Source null
                                                              tumor histology
                                                              Source null
                                                              use intent
                                                              unclear
                                                              Passage 10 · unclassified context
                                                              application numbers
                                                              1. NDA014901
                                                              brand names
                                                              1. KENALOG-40
                                                              classification reasons
                                                              1. no_unambiguous_positive_indication_predicate
                                                              clinical review status
                                                              pending
                                                              content role
                                                              unclassified_context
                                                              context span
                                                              end
                                                              2288
                                                              end exclusive
                                                              true
                                                              exact text
                                                              primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptom
                                                              label id
                                                              5914e470-3f8e-4d98-addc-fdb60423a188
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                              start
                                                              1757
                                                              current approval status
                                                              not_reconciled
                                                              duplicate text group
                                                              dup-636d93ea7f4b84a54be8
                                                              extraction review status
                                                              automated_candidate_pending_source_review
                                                              generic names
                                                              1. TRIAMCINOLONE ACETONIDE
                                                              id
                                                              ind-span-8a2c2f7468e73978be0d
                                                              label id
                                                              5914e470-3f8e-4d98-addc-fdb60423a188
                                                              positive predicate support span
                                                              Source null
                                                              qualifier mentions
                                                                regulatory links
                                                                  schema version
                                                                  0.1.0
                                                                  source batch sha256
                                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                  source defined aliases
                                                                    source span
                                                                    end
                                                                    2088
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
                                                                    label id
                                                                    5914e470-3f8e-4d98-addc-fdb60423a188
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                    start
                                                                    1957
                                                                    source url
                                                                    https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                                    spl effective date
                                                                    2026-01-05
                                                                    spl set id
                                                                    4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                                    spl version
                                                                    23
                                                                    structured fields status
                                                                    not_extracted_no_values_inferred_from_mentions
                                                                    structured indication
                                                                    age
                                                                    Source null
                                                                    approval pathway
                                                                    Source null
                                                                    biomarker and test
                                                                    Source null
                                                                    disease stage
                                                                    Source null
                                                                    limitations
                                                                    Source null
                                                                    line
                                                                    Source null
                                                                    prior therapy
                                                                    Source null
                                                                    regimen
                                                                    Source null
                                                                    tumor histology
                                                                    Source null
                                                                    use intent
                                                                    unclear
                                                                    Passage 11 · unclassified context
                                                                    application numbers
                                                                    1. NDA014901
                                                                    brand names
                                                                    1. KENALOG-40
                                                                    classification reasons
                                                                    1. no_unambiguous_positive_indication_predicate
                                                                    clinical review status
                                                                    pending
                                                                    content role
                                                                    unclassified_context
                                                                    context span
                                                                    end
                                                                    2505
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    ar inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spo
                                                                    label id
                                                                    5914e470-3f8e-4d98-addc-fdb60423a188
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                    start
                                                                    1889
                                                                    current approval status
                                                                    not_reconciled
                                                                    duplicate text group
                                                                    dup-df5f9a1a964d56cb12ab
                                                                    extraction review status
                                                                    automated_candidate_pending_source_review
                                                                    generic names
                                                                    1. TRIAMCINOLONE ACETONIDE
                                                                    id
                                                                    ind-span-986f305291bc225e3951
                                                                    label id
                                                                    5914e470-3f8e-4d98-addc-fdb60423a188
                                                                    positive predicate support span
                                                                    Source null
                                                                    qualifier mentions
                                                                      regulatory links
                                                                        schema version
                                                                        0.1.0
                                                                        source batch sha256
                                                                        bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                        source defined aliases
                                                                          source span
                                                                          end
                                                                          2305
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
                                                                          label id
                                                                          5914e470-3f8e-4d98-addc-fdb60423a188
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                          start
                                                                          2089
                                                                          source url
                                                                          https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                                          spl effective date
                                                                          2026-01-05
                                                                          spl set id
                                                                          4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                                          spl version
                                                                          23
                                                                          structured fields status
                                                                          not_extracted_no_values_inferred_from_mentions
                                                                          structured indication
                                                                          age
                                                                          Source null
                                                                          approval pathway
                                                                          Source null
                                                                          biomarker and test
                                                                          Source null
                                                                          disease stage
                                                                          Source null
                                                                          limitations
                                                                          Source null
                                                                          line
                                                                          Source null
                                                                          prior therapy
                                                                          Source null
                                                                          regimen
                                                                          Source null
                                                                          tumor histology
                                                                          Source null
                                                                          use intent
                                                                          unclear
                                                                          Passage 12 · unclassified context
                                                                          application numbers
                                                                          1. NDA014901
                                                                          brand names
                                                                          1. KENALOG-40
                                                                          classification reasons
                                                                          1. no_unambiguous_positive_indication_predicate
                                                                          clinical review status
                                                                          pending
                                                                          content role
                                                                          unclassified_context
                                                                          context span
                                                                          end
                                                                          2856
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          ses: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injectio
                                                                          label id
                                                                          5914e470-3f8e-4d98-addc-fdb60423a188
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                          start
                                                                          2106
                                                                          current approval status
                                                                          not_reconciled
                                                                          duplicate text group
                                                                          dup-9aafa6352c4e1bd8532e
                                                                          extraction review status
                                                                          automated_candidate_pending_source_review
                                                                          generic names
                                                                          1. TRIAMCINOLONE ACETONIDE
                                                                          id
                                                                          ind-span-0f9e4add811cf101d251
                                                                          label id
                                                                          5914e470-3f8e-4d98-addc-fdb60423a188
                                                                          positive predicate support span
                                                                          Source null
                                                                          qualifier mentions
                                                                            regulatory links
                                                                              schema version
                                                                              0.1.0
                                                                              source batch sha256
                                                                              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                              source defined aliases
                                                                                source span
                                                                                end
                                                                                2656
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
                                                                                label id
                                                                                5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                                start
                                                                                2306
                                                                                source url
                                                                                https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                                                spl effective date
                                                                                2026-01-05
                                                                                spl set id
                                                                                4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                                                spl version
                                                                                23
                                                                                structured fields status
                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                structured indication
                                                                                age
                                                                                Source null
                                                                                approval pathway
                                                                                Source null
                                                                                biomarker and test
                                                                                Source null
                                                                                disease stage
                                                                                Source null
                                                                                limitations
                                                                                Source null
                                                                                line
                                                                                Source null
                                                                                prior therapy
                                                                                Source null
                                                                                regimen
                                                                                Source null
                                                                                tumor histology
                                                                                Source null
                                                                                use intent
                                                                                unclear
                                                                                Passage 13 · unclassified context
                                                                                application numbers
                                                                                1. NDA014901
                                                                                brand names
                                                                                1. KENALOG-40
                                                                                classification reasons
                                                                                1. no_unambiguous_positive_indication_predicate
                                                                                clinical review status
                                                                                pending
                                                                                content role
                                                                                unclassified_context
                                                                                context span
                                                                                end
                                                                                2942
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patie
                                                                                label id
                                                                                5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                                start
                                                                                2457
                                                                                current approval status
                                                                                not_reconciled
                                                                                duplicate text group
                                                                                dup-2ca34712c98f10082004
                                                                                extraction review status
                                                                                automated_candidate_pending_source_review
                                                                                generic names
                                                                                1. TRIAMCINOLONE ACETONIDE
                                                                                id
                                                                                ind-span-179b57be3e1b86f38f45
                                                                                label id
                                                                                5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                positive predicate support span
                                                                                Source null
                                                                                qualifier mentions
                                                                                  regulatory links
                                                                                    schema version
                                                                                    0.1.0
                                                                                    source batch sha256
                                                                                    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                    source defined aliases
                                                                                      source span
                                                                                      end
                                                                                      2742
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
                                                                                      label id
                                                                                      5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                                      start
                                                                                      2657
                                                                                      source url
                                                                                      https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                                                      spl effective date
                                                                                      2026-01-05
                                                                                      spl set id
                                                                                      4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                                                      spl version
                                                                                      23
                                                                                      structured fields status
                                                                                      not_extracted_no_values_inferred_from_mentions
                                                                                      structured indication
                                                                                      age
                                                                                      Source null
                                                                                      approval pathway
                                                                                      Source null
                                                                                      biomarker and test
                                                                                      Source null
                                                                                      disease stage
                                                                                      Source null
                                                                                      limitations
                                                                                      Source null
                                                                                      line
                                                                                      Source null
                                                                                      prior therapy
                                                                                      Source null
                                                                                      regimen
                                                                                      Source null
                                                                                      tumor histology
                                                                                      Source null
                                                                                      use intent
                                                                                      unclear
                                                                                      Passage 14 · positive indication candidate
                                                                                      application numbers
                                                                                      1. NDA014901
                                                                                      brand names
                                                                                      1. KENALOG-40
                                                                                      classification reasons
                                                                                      1. explicit_positive_indication_predicate
                                                                                      2. no_tumor_directed_keyword_in_positive_statement
                                                                                      clinical review status
                                                                                      pending
                                                                                      content role
                                                                                      positive_indication_candidate
                                                                                      context span
                                                                                      end
                                                                                      3137
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      oid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
                                                                                      label id
                                                                                      5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                                      start
                                                                                      2543
                                                                                      current approval status
                                                                                      not_reconciled
                                                                                      duplicate text group
                                                                                      dup-8501b0f7db6d198a14e3
                                                                                      extraction review status
                                                                                      automated_candidate_pending_source_review
                                                                                      generic names
                                                                                      1. TRIAMCINOLONE ACETONIDE
                                                                                      id
                                                                                      ind-span-53861a3e3a7b77895bb5
                                                                                      label id
                                                                                      5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                      positive predicate support span
                                                                                      end
                                                                                      2871
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      are indicated
                                                                                      label id
                                                                                      5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                                      start
                                                                                      2858
                                                                                      qualifier mentions
                                                                                        regulatory links
                                                                                          schema version
                                                                                          0.1.0
                                                                                          source batch sha256
                                                                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                          source defined aliases
                                                                                            source span
                                                                                            end
                                                                                            3137
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
                                                                                            label id
                                                                                            5914e470-3f8e-4d98-addc-fdb60423a188
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
                                                                                            start
                                                                                            2743
                                                                                            source url
                                                                                            https://api.fda.gov/drug/label.json?search=id%3A%225914e470-3f8e-4d98-addc-fdb60423a188%22
                                                                                            spl effective date
                                                                                            2026-01-05
                                                                                            spl set id
                                                                                            4ce116aa-b330-4da9-9cdd-ba8e6be0c4ad
                                                                                            spl version
                                                                                            23
                                                                                            structured fields status
                                                                                            not_extracted_no_values_inferred_from_mentions
                                                                                            structured indication
                                                                                            age
                                                                                            Source null
                                                                                            approval pathway
                                                                                            Source null
                                                                                            biomarker and test
                                                                                            Source null
                                                                                            disease stage
                                                                                            Source null
                                                                                            limitations
                                                                                            Source null
                                                                                            line
                                                                                            Source null
                                                                                            prior therapy
                                                                                            Source null
                                                                                            regimen
                                                                                            Source null
                                                                                            tumor histology
                                                                                            Source null
                                                                                            use intent
                                                                                            non_oncology_or_unclear_candidate

                                                                                            Preserved source evidence · Not medical advice